CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer
2018 · The Oncologist · 93 citations
https://doi.org/10.1634/theoncologist.2017-0674
N
Naomi Kiyota
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
347
Papers
14.7K
Citations
44
h-index
126
i10-index
Naomi Kiyota is an academic researcher from Aichi Medical University. The author has contributed to research in topics: Head and Neck Cancer Studies & Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers. The author has an h-index of 44, co-authored 295 publications.
ORCID: 0000-0001-8021-6116Papers by this author
worksPan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck
2021 · ESMO Open · 74 citations
https://doi.org/10.1016/j.esmoop.2021.100309
Japanese Clinical Practice Guideline for Head and Neck Cancer
2017 · Auris Nasus Larynx · 66 citations
https://doi.org/10.1016/j.anl.2017.02.004
Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
2011 · Investigational New Drugs · 61 citations
https://doi.org/10.1007/s10637-011-9637-1
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
2022 · The Oncologist · 47 citations
https://doi.org/10.1093/oncolo/oyab036
Optimal use of lenvatinib in the treatment of advanced thyroid cancer
2017 · Cancers of the Head & Neck · 25 citations
https://doi.org/10.1186/s41199-017-0026-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat